GlassScriptPhysician profile
Samantha M Lewis
NPI 1619222494
$7,073.08
in general payments reported to CMS, 2019-2025
58 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,703 · 2022: $1,424 · 2023: $1,466 · 2024: $1,547 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.06 |
| Education | $145.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.37 | 2021-2025 | |
| Novo Nordisk INC | $782.38 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $701.57 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $627.76 | 2021-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $432.62 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $254.43 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.06 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $223.42 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $214.94 | 2021-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $191.80 | 2021-2024 | Rexulti |
| Abbott Laboratories | $175.84 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $171.01 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $156.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $135.23 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.88 | 2021-2023 | Xifaxan, Trulance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.